New research in The FASEB Journal suggests that a chimera design of DNA and small DNA with a companion contrast agent to facilitate uptake allows antibodies to cross cell membranes
Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes. Once across these membranes, the tissues being evaluated can be imaged a much greater level of detail than what is possible now.
This could significantly impact the use of gene therapy and stem cell therapy, as well as lead to better diagnosis and treatment of cancer, Alzheimer’s disease, viral infections, HIV, herpes and prion diseases.
“Dr. McCoy does not have to perform a biopsy to know the disorder and cure patients without surgery in Star Trek,” said Philip K. Liu, Ph.D., a researcher involved in the work from the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital in Charlestown, Massachusetts. “This finding avoids biopsy and it makes a ‘McCoy diagnosis’ one step closer to reality.”
To make this advance, Liu and colleagues used three groups of mice. This first group received a complete chimera (antibodies to rhodopsin linked to a reporter agent and small DNA), the second group received a chimera without DNA. A third group had damaged retinas and a less rhodopsin. The first group showed a presence of the chimera in the retina using MRI (in vivo) or TEM (ex vivo). Uptake and targeting of complete chimera were compared in the third group and the first group. Results showed that the third group had significantly less uptake of chimera.
“There will be a time when biopsies are considered primitive,” said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, “and as developments in imaging technology and techniques improve our capabilities, the need for invasive, and sometimes painful, biopsies is greatly decreased.”
The Latest on: Invasive biopsies
via Google News
The Latest on: Invasive biopsies
- TruGraf & TRAC Combine to Deliver the Most Comprehensive, Noninvasive Kidney Rejection Diagnosticson May 30, 2020 at 7:26 am
MANSFIELD, Mass. and KANSAS CITY, Mo., May 30, 2020 /PRNewswire/ -- Transplant Genomics, Inc. ('TGI') and Viracor announce the first available ...
- Are Patients With Ductal Carcinoma In Situ Being Overtreated?on May 29, 2020 at 12:34 pm
A study compared the risk of ipsilateral invasive breast cancer in patients with DCIS undergoing breast-conserving therapy with surveillance alone.
- Liquid Biopsy Market Size is Set to Record 21.54% CAGR during forecast 2027on May 28, 2020 at 7:58 pm
Selbyville, Delaware — The 2019-2027 report on Global Liquid Biopsy Market explores the essential factors of Liquid Biopsy Market industry covering current scenario, market demand information, ...
- Global Liquid Biopsy Market Size to grow with 21.54% CAGR through 2027on May 26, 2020 at 11:08 am
Selbyville, Delaware According to Market Study Report, Provides A Detailed Overview Of Liquid Biopsy Market With Respect To The Pivotal Drivers Influencing The Revenue Graph Of This Business Sphere.
- Epic Sciences to Present Multiple Abstracts at ASCO 2020 Highlighting the Importance of CTCs in Liquid Biopsyon May 26, 2020 at 6:00 am
Epic Sciences, Inc. today announced that it will present three abstracts at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held from May 29 – June 2, 2020. Epic ...
- Smart Biopsy Devices Market to 2027 | Top Key Players are Dune Medical Devices., innoMedicus Ltd., Intuitive Surgical, Canon Medical Systems, USAon May 20, 2020 at 1:39 pm
The major players covered in the smart biopsy devices market report are Dune Medical Devices., innoMedicus Ltd., Intuitive Surgical, Canon Medical Systems, USA., Boston Scientific Corporation., BD, ...
- Fluorescence - A non invasive bedside technique to detect Cervical canceron May 20, 2020 at 8:21 am
A team of researchers at Tufts University's School of Engineering and its School of Medicine, and physicians at Tufts Medical Center have developed a ...
- Making liquid biopsy a realityon May 17, 2020 at 4:00 am
Liquid Biopsy is a blood test that detects changes in normal DNA sequence shed by cancer cells in the blood. It can be used to predict cancer relapse well ahead of time even before tumors are seen on ...
- Liquid Biopsy in Cancer Diagnosis and Treatmenton May 8, 2020 at 5:25 pm
This noninvasive approach can detect tumors and cancer progression earlier than invasive biopsy's with great accuracy." Mostly clear for a while, then increasing clouds with a shower in spots late.
- Liquid Biopsy in Cancer Diagnosis and Treatmenton May 8, 2020 at 5:06 pm
This noninvasive approach can detect tumors and cancer progression earlier than invasive biopsy's with great accuracy." Experimental Biology and Medicine is a global journal dedicated to the ...
via Bing News